vs
Side-by-side financial comparison of BIOMERICA INC (BMRA) and Lucid Diagnostics Inc. (LUCD). Click either name above to swap in a different company.
Lucid Diagnostics Inc. is the larger business by last-quarter revenue ($1.2M vs $1.2M, roughly 1.0× BIOMERICA INC). BIOMERICA INC runs the higher net margin — -109.1% vs -858.5%, a 749.5% gap on every dollar of revenue. On growth, Lucid Diagnostics Inc. posted the faster year-over-year revenue change (3.3% vs -26.0%). Over the past eight quarters, Lucid Diagnostics Inc.'s revenue compounded faster (7.9% CAGR vs -12.1%).
Biomerica Inc. is a global medical technology company that develops, manufactures and markets diagnostic test kits and related medical products. Its portfolio covers gastrointestinal conditions, infectious diseases, food intolerances and point-of-care testing solutions, serving clinical labs, healthcare providers and retail healthcare segments across North America, Europe and Asia.
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics firm focused on non-invasive screening tests for upper gastrointestinal diseases, including early detection of esophageal cancer and pre-cancerous lesions. It mainly serves healthcare providers and clinical partners across the United States, targeting at-risk patient populations.
BMRA vs LUCD — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.2M |
| Net Profit | $-1.3M | $-10.4M |
| Gross Margin | 4.2% | — |
| Operating Margin | -113.5% | -971.0% |
| Net Margin | -109.1% | -858.5% |
| Revenue YoY | -26.0% | 3.3% |
| Net Profit YoY | -38.9% | 16.0% |
| EPS (diluted) | $-0.45 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.4M | $1.2M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | $1.1M | $828.0K | ||
| Q4 24 | $1.6M | $1.2M | ||
| Q3 24 | $1.8M | $1.2M | ||
| Q2 24 | $1.1M | $976.0K | ||
| Q1 24 | $1.0M | $1.0M |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $2.0K | $-10.4M | ||
| Q2 25 | — | $-4.4M | ||
| Q1 25 | $-1.2M | $-26.9M | ||
| Q4 24 | $-950.0K | $-11.5M | ||
| Q3 24 | $-1.3M | $-12.4M | ||
| Q2 24 | $-1.4M | $-11.0M | ||
| Q1 24 | $-1.9M | $-10.6M |
| Q4 25 | 4.2% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 16.0% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -14.7% | — |
| Q4 25 | -113.5% | — | ||
| Q3 25 | -81.0% | -971.0% | ||
| Q2 25 | — | -978.8% | ||
| Q1 25 | -108.1% | -1508.1% | ||
| Q4 24 | -60.7% | -1033.8% | ||
| Q3 24 | -75.7% | -997.8% | ||
| Q2 24 | -136.6% | -1146.7% | ||
| Q1 24 | -196.7% | -1078.1% |
| Q4 25 | -109.1% | — | ||
| Q3 25 | 0.1% | -858.5% | ||
| Q2 25 | — | -381.7% | ||
| Q1 25 | -103.9% | -3249.8% | ||
| Q4 24 | -58.1% | -964.2% | ||
| Q3 24 | -72.8% | -1055.5% | ||
| Q2 24 | -127.1% | -1127.6% | ||
| Q1 24 | -188.6% | -1060.1% |
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $0.00 | $-0.10 | ||
| Q2 25 | — | $-0.08 | ||
| Q1 25 | $-0.48 | $-0.52 | ||
| Q4 24 | $-0.06 | $-0.17 | ||
| Q3 24 | $-0.63 | $-0.25 | ||
| Q2 24 | $-2.57 | $-0.23 | ||
| Q1 24 | $-0.11 | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $47.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.4M | $25.8M |
| Total Assets | $6.0M | $53.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.5M | — | ||
| Q3 25 | $3.1M | $47.3M | ||
| Q2 25 | — | $31.1M | ||
| Q1 25 | $3.1M | $25.2M | ||
| Q4 24 | $2.4M | $22.4M | ||
| Q3 24 | $2.8M | $14.5M | ||
| Q2 24 | $4.2M | $24.9M | ||
| Q1 24 | $5.3M | $24.8M |
| Q4 25 | $4.4M | — | ||
| Q3 25 | $5.2M | $25.8M | ||
| Q2 25 | — | $7.9M | ||
| Q1 25 | $5.5M | $-5.4M | ||
| Q4 24 | $5.1M | $5.4M | ||
| Q3 24 | $5.3M | $6.3M | ||
| Q2 24 | $6.6M | $16.0M | ||
| Q1 24 | $7.8M | $11.9M |
| Q4 25 | $6.0M | — | ||
| Q3 25 | $6.9M | $53.2M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | $7.4M | $32.8M | ||
| Q4 24 | $7.3M | $30.7M | ||
| Q3 24 | $7.9M | $22.6M | ||
| Q2 24 | $9.3M | $34.1M | ||
| Q1 24 | $10.3M | $32.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-991.0K | $-10.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-991.0K | — | ||
| Q3 25 | $-268.0K | $-10.9M | ||
| Q2 25 | — | $-10.5M | ||
| Q1 25 | $-1.0M | $-12.5M | ||
| Q4 24 | $-791.0K | $-9.9M | ||
| Q3 24 | $-1.3M | $-10.2M | ||
| Q2 24 | $-1.0M | $-11.5M | ||
| Q1 24 | $-1.8M | $-12.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -95.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
